I hope that the following information will be of help:
Novartis and the FDA have notified healthcare professionals in the US about revisions to the precautions section of the prescribing information for imatinib (known by brand name Gleevec in US), describing the occasional occurrence of severe congestive heart failure and left ventricular dysfunction. Most of the cases involved patients who had other co-morbidities and risk factors, including advanced age and previous medical history of cardiac disease. It is recommended that patients with cardiac disease or risk factors for cardiac failure should be monitored carefully and any patients with signs or symptoms consistent with cardiac failure should be evaluated and treated.
Paul